Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

ss for the year ended June 30, 2011 compared to the net loss for the year ended June 30, 2010 was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements.

RevenueRevenues in the quarter ended June 30, 2011 were $0.2 million, compared to $0.7 million for the same period in 2010.  For the year ended June 30, 2011, revenues were $1.5 million, compared to $14.2 million for year ended June 30, 2010.  

Costs and ExpensesFor the quarter ended June 30, 2011, total operating expenses were $4.7 million compared to $4.9 million for the comparable quarter of 2010.  For the year ended June 30, 2011, total operating expenses were $15.1 million compared to $17.2 million for the year ended June 30, 2010. The decreases in operating expenses for the respective periods is the result of reducing staffing levels pursuant to Palatin's strategic decision announced in September 2010.

Cash positionPalatin's cash and cash equivalents were $18.9 million as of June 30, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $2.8 million as of June 30, 2011 compared to $2.4 million as of June 30, 2010.  

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on September 22, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-800-281-7970 (domestic) or 1-913-312-0671 (international), pass code 9488233.  The webcas
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... 28, 2014 The ability for organizations ... that will allow individuals to perform at the highest ... for employers looking to compete in this post–recession era. ... this trend, as the sector increasingly focuses on the ... which will have real results on the organization's development ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... diaDexus, Inc. (OTC Bulletin Board: DDXS ... commercialization of patent-protected in vitro diagnostic products ... the company, formerly known as VaxGen, Inc. and traded ... (VXGN), has been renamed diaDexus, Inc. diaDexus, common stock ...
... and latest developments ... ... --> ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 2Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 3Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 4Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 5Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 6Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 7Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 8
(Date:8/29/2014)... is available in German . ... in the natural nitrogen cycle on Earth and in ... were thought to depend on nitrite as their source ... Holger Daims, a microbiologist at the University of Vienna, ... as an alternative source of energy. The oxidation of ...
(Date:8/29/2014)... - The rise of the Tibetan plateau -- the ... is important for both its profound effect on climate ... published in GSA Bulletin , Katharine Huntington and ... thermometry -- using modern and fossil snail shells to ... southwestern Tibet. , Views range widely on the ...
(Date:8/28/2014)... available in German . ... its name to a striking pattern of blue stripes alternating ... reflective silvery cells, and yellow cells emerge during growth in ... a multilayered mosaic to compose the characteristic colour pattern. ... have to interact to form proper stripes, the embryonic origin ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... the Robarts Research Institute at The University of Western ... used a unique genetically-modified mouse line to reveal a ... led by Marco Prado, Robert Gros and Vania Prado ... how the decreased release of the neurotransmitter acetylcholine, a ...
... Cancer Institute have further developed a potential new treatment ... cancer cells, removing them from the body. The treatment, ... using samples from human cancer patients. The results appear ... are primarily interested in developing an effective method to ...
... (Boston) Boston University School of Medicine (BUSM) ... physiology, with joint appointments in biomedical engineering and medicine, ... Lipids. This award is being bestowed by ... in the application of nuclear magnetic resonance methods to ...
Cached Biology News:Genetically-modified mice reveal another mechanism contributing to heart failure 2Magnetic nanoparticles show promise for combating human cancer 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Antibody to CRF The ... ovine CRF sequence that it ... fibres are found in the ... brain in colchicine treated 4% ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Biology Products: